0 22 Glucocorticoid-induced glucocorticoid-induced JJ 23 32 apoptosis apoptosis NN 33 36 and and CC 37 47 regulation regulation NN 48 50 of of IN 51 60 NF-kappaB NF-kappaB NNP 61 69 activity activity NN 70 72 in in IN 73 78 human human JJ 79 87 leukemic leukemic JJ 88 89 T t NN 90 95 cells cell NNS 95 96 . . . 98 120 Glucocorticoid-induced glucocorticoid-induced JJ 121 130 apoptosis apoptosis NN 131 134 was be VBD 135 147 investigated investigate VBN 148 150 in in IN 151 175 glucocorticoid-sensitive glucocorticoid-sensitive JJ 176 182 6TG1.1 6tg1.1 NN 183 186 and and CC 187 196 resistant resistant JJ 197 206 ICR27TK.3 icr27tk.3 NN 207 212 human human JJ 213 221 leukemic leukemic JJ 222 223 T t NN 224 229 cells cell NNS 229 230 . . . 231 240 Following follow VBG 241 255 glucocorticoid glucocorticoid NN 256 265 treatment treatment NN 266 268 of of IN 269 275 6TG1.1 6tg1.1 NN 276 281 cells cell NNS 281 282 , , , 283 292 chromatin chromatin NN 293 306 fragmentation fragmentation NN 307 310 was be VBD 311 319 observed observe VBN 320 325 after after IN 326 327 a a DT 328 333 delay delay NN 334 336 of of IN 337 339 24 24 CD 340 342 h. h. NN 343 356 Fragmentation Fragmentation NNP 357 360 was be VBD 361 364 not not RB 365 373 observed observe VBN 374 376 in in IN 377 386 ICR27TK.3 icr27tk.3 NN 387 392 cells cell NNS 393 403 containing contain VBG 404 410 mutant mutant JJ 411 425 glucocorticoid glucocorticoid NN 426 435 receptors receptor NNS 436 437 ( ( ( 437 442 L753F L753F NNP 442 443 ) ) ) 444 448 that that WDT 449 452 are be VBP 453 473 activation-deficient activation-deficient JJ 474 477 but but CC 478 484 retain retain VBP 485 488 the the DT 489 496 ability ability NN 497 499 to to TO 500 507 repress repress VB 508 512 AP-1 ap-1 NN 513 521 activity activity NN 521 522 . . . 523 526 Nor nor CC 527 530 was be VBD 531 544 fragmentation fragmentation NN 545 553 observed observe VBN 554 559 after after IN 560 569 treatment treatment NN 570 574 with with IN 575 582 RU38486 RU38486 NNP 582 583 , , , 584 594 indicating indicate VBG 595 599 that that IN 600 610 repression repression NN 611 613 of of IN 614 618 AP-1 ap-1 NN 619 627 activity activity NN 628 630 is be VBZ 631 634 not not RB 635 643 involved involve VBN 643 644 . . . 645 647 As as IN 648 657 described describe VBN 658 660 in in IN 661 666 other other JJ 667 674 systems system NNS 674 675 , , , 676 689 fragmentation fragmentation NN 690 698 required require VBD 699 706 ongoing ongoing JJ 707 714 protein protein NN 715 724 synthesis synthesis NN 724 725 . . . 726 733 However however RB 733 734 , , , 735 745 inhibition inhibition NN 746 748 of of IN 749 756 protein protein NN 757 766 synthesis synthesis NN 767 771 with with IN 772 785 cycloheximide cycloheximide NN 786 793 anytime anytime RB 794 800 during during IN 801 804 the the DT 805 810 first first JJ 811 813 18 18 CD 814 815 h h NN 816 818 of of IN 819 826 steroid steroid NN 827 836 treatment treatment NN 837 840 was be VBD 841 843 as as RB 844 853 effective effective JJ 854 856 in in IN 857 865 blocking block VBG 866 875 chromatin chromatin NN 876 889 fragmentation fragmentation NN 890 892 as as IN 893 903 inhibition inhibition NN 904 907 for for IN 908 911 the the DT 912 918 entire entire JJ 919 925 period period NN 925 926 , , , 927 937 suggesting suggest VBG 938 942 that that IN 943 952 synthesis synthesis NN 953 955 of of IN 956 957 a a DT 958 967 component component NN 968 972 with with IN 973 974 a a DT 975 980 rapid rapid JJ 981 989 turnover turnover NN 990 994 rate rate NN 995 997 is be VBZ 998 1006 required require VBN 1006 1007 . . . 1008 1021 Dexamethasone Dexamethasone NNP 1022 1031 treatment treatment NN 1032 1042 completely completely RB 1043 1050 blocked block VBD 1051 1076 12-O-tetradecanoylphorbol 12-O-tetradecanoylphorbol NNP 1077 1087 13-acetate 13-acetate NN 1088 1097 induction induction NN 1098 1100 of of IN 1101 1108 nuclear nuclear JJ 1109 1122 factor-kappaB factor-kappaB NNP 1123 1124 ( ( ( 1124 1133 NF-kappaB NF-kappaB NNP 1133 1134 ) ) ) 1135 1143 activity activity NN 1144 1147 and and CC 1148 1156 elicited elicit VBD 1157 1159 an an DT 1160 1168 increase increase NN 1169 1171 in in IN 1172 1175 the the DT 1176 1182 amount amount NN 1183 1185 of of IN 1186 1200 immunoreactive immunoreactive JJ 1201 1208 IkappaB IkappaB NNP 1209 1214 alpha alpha NN 1215 1217 in in IN 1218 1227 sensitive sensitive JJ 1228 1234 6TG1.1 6tg1.1 NN 1235 1240 cells cell NNS 1241 1244 but but CC 1245 1248 not not RB 1249 1251 in in IN 1252 1261 resistant resistant JJ 1262 1271 ICR27TK.3 icr27tk.3 NN 1272 1277 cells cell NNS 1277 1278 . . . 1279 1281 In in IN 1282 1290 addition addition NN 1290 1291 , , , 1292 1296 mild mild JJ 1297 1306 detergent detergent NN 1307 1316 treatment treatment NN 1317 1319 of of IN 1320 1324 cell cell NN 1325 1333 extracts extract NNS 1334 1343 indicated indicate VBD 1344 1348 that that IN 1349 1350 a a DT 1351 1362 substantial substantial JJ 1363 1369 amount amount NN 1370 1372 of of IN 1373 1384 cytoplasmic cytoplasmic JJ 1385 1394 NF-kappaB nf-kappab NN 1395 1397 is be VBZ 1398 1407 complexed complexe VBN 1408 1412 with with IN 1413 1420 IkappaB IkappaB NNP 1421 1426 alpha alpha NN 1427 1429 or or CC 1430 1434 some some DT 1435 1440 other other JJ 1441 1451 inhibitory inhibitory JJ 1452 1458 factor factor NN 1458 1459 . . . 1460 1465 These these DT 1466 1473 results result NNS 1474 1481 suggest suggest VBP 1482 1486 that that IN 1487 1496 induction induction NN 1497 1499 of of IN 1500 1501 a a DT 1502 1508 labile labile JJ 1509 1519 inhibitory inhibitory JJ 1520 1526 factor factor NN 1527 1531 such such JJ 1532 1534 as as IN 1535 1542 IkappaB IkappaB NNP 1543 1548 alpha alpha NN 1549 1552 may may MD 1553 1563 contribute contribute VB 1564 1566 to to TO 1567 1589 glucocorticoid-induced glucocorticoid-induced JJ 1590 1599 apoptosis apoptosis NN 1599 1600 . . .